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Abstract 298 
High blood pressure is a major risk factor for cardiovascular disease and premature death. However, there is 299 
limited knowledge on specific causal genes and pathways. To better understand the genetics of blood 300 
pressure, we genotyped 242,296 rare, low-frequency and common genetic variants in up to ~192,000 301 
individuals, and used ~155,063 samples for independent replication. We identified 31 novel blood pressure 302 
or hypertension associated genetic regions in the general population, including three rare missense variants 303 
in RBM47, COL21A1 and RRAS with larger effects (>1.5mmHg/allele) than common variants. Multiple rare, 304 
nonsense and missense variant associations were found in A2ML1 and a low-frequency nonsense variant in 305 
ENPEP was identified. Our data extend the spectrum of allelic variation underlying blood pressure traits and 306 
hypertension, provide new insights into the pathophysiology of hypertension and indicate new targets for 307 
clinical intervention.  308 
  309 
Introduction 310 
High blood pressure (BP) or hypertension is a highly prevalent chronic disorder. It is estimated to be 311 
responsible for a larger proportion of global disease burden and premature mortality than any other disease 312 
risk factor1. Elevated systolic and/or diastolic BP increases the risk of several cardiovascular disorders 313 
including stroke, coronary heart disease (CHD), heart failure, peripheral arterial disease and abdominal 314 
aortic aneurysms2. BP is a complex, heritable, polygenic phenotype for which genome-wide association 315 
studies (GWAS) have identified over 67 genetic regions associated with BP and/or hypertension to date3-11. 316 
These variants are common (minor allele frequency, MAF≥0.05), mostly map to intronic or intergenic 317 
regions, with the causal alleles and genes not readily identified due to linkage disequilibrium (LD)4,5, and 318 
explain only ~2% of trait variance12. Low-frequency (0.01<MAF<0.05) and rare (MAF≤0.01) single 319 
nucleotide variants (SNVs), predominantly unexplored by GWAS may have larger phenotypic effects than 320 
common SNVs13, and may help to explain the missing heritability, and identify causative genes as 321 
demonstrated previously14.  322 
To identify novel coding variants and loci influencing BP traits and hypertension we performed the largest 323 
meta-analysis to date that included a total of ~350,000 individuals, directly genotyped with the Exome chip. 324 
The Exome chip contains ~240,000 mostly rare and low-frequency variants (Methods). A single-variant 325 
discovery analysis was performed, and candidate SNVs were taken forward for validation using independent 326 
replication samples. Gene-based tests were used to identify BP associated genes harboring multiple rare 327 
variant associations.  We next assessed whether the newly identified BP associated SNVs were associated 328 
with expression levels of nearby genes, and tested these variants in aggregate for a causal association of BP 329 
with other cardiovascular traits and risk factors. Our findings highlight the contribution of rare variants in 330 
the aetiology of blood pressure in the general population, and provide new insights into the pathophysiology 331 
of hypertension.   332 
 333 
Results 334 
Discovery of single variant BP associations  335 
We genotyped 192,763 individuals from 51 studies, and assessed association of 242,296 SNVs with 336 
diastolic BP (DBP), systolic BP (SBP), pulse pressure (PP) and hypertension (HTN; Supplementary Tables 337 
1, 2 and 3; Methods). An overview of the SNV discovery study design is given in Figure 1.  A fixed effects 338 
meta-analysis for each trait was performed using study-level association summary statistics from i) samples 339 
of European (EUR) ancestry (up to 165,276 individuals), and ii) a trans-ethnic meta-analysis of the EUR and 340 
additional South Asian (SAS) ancestry samples (EUR_SAS; up to 192,763 individuals). Two analyses of 341 
DBP, SBP and PP were performed, one in which the trait was inverse normal transformed and a second in 342 
which the raw phenotype was analysed. Both sets of results were consistent (Methods), therefore to 343 
minimise sensitivity to deviations from normality in the analysis of rare variants, the results from the 344 
analyses of the transformed traits were used for discovery. Strong correlations between the BP traits were 345 
observed across studies (Methods), hence no adjustment of significance thresholds for independent trait 346 
testing was applied.  347 
The discovery meta-analyses identified 50 genomic regions with genome-wide significant (GWS) evidence 348 
of association with at least one of the four BP traits tested (P<5x10-8; Supplementary Table 4). There were 349 
45 regions associated in the EUR_SAS samples, of which 13 were novel (Figure 2). An additional five 350 
regions were GWS in the EUR only meta-analyses of which two were novel (Supplementary Figure 1).  In 351 
total, 16 genomic regions were identified that were GWS for at least one BP trait that have not been 352 
previously reported. 353 
Replication of single variant BP associations  354 
Next we sought support for our findings, in an independent replication dataset comprising of 18 studies, 16 355 
of which were from the Cohorts for Heart and Aging Research in Genomic Epidemiology+ (CHARGE+) 356 
exome chip blood pressure consortium (Figure 1; Liu et al. Nature Genetics, submitted).  Variants were 357 
selected for replication first using the larger (transformed) EUR_SAS data, with additional variants from the 358 
(transformed) EUR data also selected. SNVs were selected if they mapped outside of known BP genomic 359 
regions and had MAF≥0.05 and P<1x10-5 or MAF<0.05 and P<1x10-4 with at least one BP trait, i.e. 360 
choosing a lower significance threshold for the selection of rare variants (full details of the selection criteria 361 
are provided in the Methods). In total 81 candidate SNVs were selected for replication (Supplementary 362 
Table 5). Eighty variants were selected from EUR_SAS (transformed) results and one SNV at the ZNF101 363 
locus from the EUR (transformed) analyses. The results for EUR_SAS and EUR were consistent 364 
(association statistics were correlated, =0.9 across ancestries for each of the traits). Of the 81 variants, 30 365 
SNVs were selected for association with DBP as the primary trait, 26 for SBP, 19 for PP and 6 for HTN, 366 
with the primary trait defined as the BP trait with the smallest association P-value in the EUR-SAS 367 
discovery analyses. 368 
Meta-analyses were performed on results from analyses of untransformed DBP, SBP, PP and HTN (as only 369 
results of untransformed traits were available from CHARGE+) in (i) up to 125,713 individuals of EUR 370 
descent, and (ii) up to 155,063 individuals of multiple ethnicities (4,632 of Hispanic descent, 22,077 of 371 
African American descent, 2,641 SAS samples with the remainder EUR; Figure 1). Given that a large 372 
proportion of the ancestries in the trans-ethnic meta-analyses were not included in our discovery samples, 373 
we used the EUR meta-analyses as the main data set for replication, but we also report any additional 374 
associations identified within the larger trans-ethnic dataset. 375 
Novel BP-SNV associations were identified based on two criteria (Figure 1; Methods). Firstly, replication of 376 
the primary BP trait-SNV association was sought at a Bonferroni adjusted P-value threshold in the 377 
replication data (P≤6.17x10-4, assuming α=0.05 for 81 SNVs tested and same direction of effect; Methods) 378 
without the need for GWS. Secondly, meta-analyses of discovery and replication results across all four 379 
(untransformed) BP traits were performed to assess the overall level of support across all samples for the 81 380 
candidate SNVs; those BP-SNV associations that were GWS (with statistical support in the replication 381 
studies; P<0.05 and the same direction of effect) were also declared as novel. 382 
 383 
Seventeen SNV-BP associations formally replicated with concordant direction of effect at a Bonferroni 384 
adjusted significance level for the primary trait. Fourteen were in the EUR meta-analyses, and amongst these 385 
was a rare non-synonymous (ns) SNV mapping to COL21A1 (Table 1, Supplementary Table 6). Three 386 
associations were in the trans-ethnic meta-analyses, these included two rare nsSNVs in RBM47 and RRAS 387 
(Table 1, Supplementary Table 7; Methods).  388 
  389 
In addition to the 17 SNV-BP trait associations that formally replicated, we identified 13 further SNV-390 
associations that were GWS in the combined (discovery and replication) meta-analyses. Ten of these were 391 
GWS in the combined EUR analyses, (Table 2; Supplementary Tables 6 and 8a), and three were GWS in the 392 
combined trans-ethnic meta-analyses (Table 2; Supplementary Tables 7 and 8b). 393 
 394 
This gives a total of 30 novel SNV-BP associations (15 SNV-DBP, 9 SNV-SBP and 6 SNV-PP; Tables 1 395 
and 2; Supplementary Figures 2 and 3). Five of the SNVs were GWS with more than one BP trait (Figure 3: 396 
Tables 1 and 2; Supplementary Table 8). Four loci (CERS5, TBX2, RGL3 and OBFC1) had GWS 397 
associations with HTN in addition to GWS associations with DBP and SBP. The PRKAG1 locus had GWS 398 
associations with both SBP and PP. 399 
 400 
Conditional analyses were performed to identify secondary signals of association within the novel BP loci. 401 
The RAREMETALWORKER (RMW) package (Methods)15 allows conditional analyses to be performed 402 
using summary level data. Hence, analyses of the transformed primary traits and HTN were re-run in RMW 403 
across the discovery studies (Figure 4).  The results of the RMW single variant tests were consistent with the 404 
initial discovery analyses (Supplementary Information). Given the RMW analyses were based on our 405 
discovery samples, the larger EUR-SAS data was used as the main analysis to increase power, but we also 406 
report any additional associations with evidence in EUR.  407 
 408 
We identified secondary independent signals of association in four loci, PREX1, PRKAG1 and RRP1B 409 
within the EUR_SAS analyses and COL21A1 in the EUR analyses (Pconditional<1x10
-4, Bonferroni adjusted 410 
for ~500 variants within each region; Methods; Supplementary Tables 9 and 10). Three independent 411 
association signals were identified in the MYH6 locus in the EUR_SAS analyses (Supplementary Table 11).  412 
 413 
Gene-based BP associations  414 
To improve statistical power to detect associations in genes harbouring rare variants, analytical methods that 415 
combine effects of variants across a gene into a single test have been devised and are implemented in the 416 
RMW package15. We applied the gene-based sequence kernel association test (SKAT)16  and Burden tests17 417 
to the RMW dataset (MAF<0.05 or MAF<0.01; Figure 4; Methods). One previously unidentified BP gene 418 
(A2ML1) was associated with HTN (P= 7.73x10-7) in the EUR_SAS studies and also in EUR studies 419 
(Supplementary Table 12; Bonferroni-corrected threshold of significance P<2.8x10-6, after adjusting for 420 
17,996 genes tested, Methods). The gene showed residual association with the primary BP trait after 421 
conditioning on the most associated SNV in the gene (Pconditional=5.00x10
-4; Supplementary Table 12), 422 
suggesting that the association is due to multiple rare variants in the gene. One nonsense variant 423 
(rs199651558, p.Arg893*, MAF=3.5x10-4) was observed, and there were multiple missense variants (Figure 424 
5).  A2ML1 encodes alpha-2-macroglobulin-like 1 protein, and is a member of the alpha macroglobulin 425 
superfamily, which comprises protease inhibitors targeting a wide range of substrates. Mutations in this gene 426 
are associated with a disorder clinically related to Noonan syndrome, a developmental disorder which 427 
involves cardiac abnormalities18. We sought replication in the CHARGE+ studies for this gene, however 428 
there was no evidence of association with HTN (P= 0.45). Given the very low frequencies of the variants 429 
involved, however, studies in which the variants are polymorphic will be required to replicate the 430 
association with HTN. The DBH gene was found to be associated with DBP using the SKAT test 431 
(P=2.88x10-6). However, this was not due to multiple rare variants as the association was driven by 432 
rs77273740 (Supplementary Table 5) and the SNV was not validated in the replication samples. 433 
 434 
Rare and common variant associations in established BP loci 435 
Of the 67 established BP loci, 35 loci were on the Exome chip (N=43 SNVs or close proxies r2>0.7). All 43 436 
SNVs had at least nominal evidence of association with BP in our discovery samples (P<0.01; 437 
Supplementary Table 13). We also assessed if any of the established BP loci contained coding variants that 438 
are associated with BP traits and in LD (r2>0.2) with the known BP variants on the Exome chip 439 
(Supplementary Table 13), using the 1000G phase 3 release for LD annotation. Focusing on SNVs that were 440 
GWS for any BP trait from our transformed discovery data for either ancestry, there were 25 coding 441 
variants, of which 6 were predicted to be damaging at loci labelled CDC25A, SLC39A8, HFE, ULK4, ST7L-442 
CAPZA1-MOV10 and CYP1A1-ULK3. Three of these are published variants at loci labelled SLC39A8, HFE 443 
and ST7-CAPZA1-MOV10. At CYP1A1-ULK3, the coding variant was in moderate LD with the reported 444 
variant, but was less significantly associated with DBP in our EUR_SAS dataset (P=2.24x10-8 compared to 445 
P=1.68x10-15 for the published variant). At the ULK4 locus the predicted damaging coding variant had 446 
similar association as the published coding variant (predicted to be benign), and prior work has already 447 
indicated several associated nsSNVs in strong LD in ULK4 19. The nsSNV within the CDC25A locus 448 
(rs11718350 in SPINK8) had similar association with DBP as the intergenic published SNV in our 449 
EUR_SAS dataset (P=2.00x10-8 compared to P=2.27x10-8 for the published variant). Overall at least 5 of 450 
the known loci are consistent with having a coding causal variant. 451 
Gene-based SKAT tests of all genes that map within 1 Mb of a previously reported SNV association 452 
(Supplementary Table 14), indicated no genes with multiple rare or low-frequency variant associations. 453 
Single variant conditional analyses showed that rs33966350, a rare nonsense variant in ENPEP (MAF=0.01) 454 
was associated with SBP (Pconditional=1.61x10
-5) in the EUR_SAS samples (Supplementary Tables 14 and 15; 455 
Methods) independently of the known SNV (rs6825911). ENPEP encodes aminopeptidase A (APA) an 456 
enzyme of the renin-angiotensin-aldosterone system (RAAS) that converts angiotensin II (AngII) to AngIII.  457 
There were no other established loci with convincing low-frequency or rare SNV associations in the 458 
EUR_SAS samples. However, HOXC4, had evidence of a second independent signal with a rare missense 459 
SNV in EUR samples (rs78731604; MAF=0.005, Pconditional= 5.76x10-5; Supplementary Table 15).  The 460 
secondary signal in the HOXC4 region, mapped to CALCOCO1, ~300kb from the known SNV. The gene 461 
association (MAF≤0.01, P=2.37x10-5) was below the required significance threshold and attributable to 462 
rs78731604, which is not predicted to have detrimental effects on protein structure. Therefore, replication of 463 
this association is required. Three loci (ST7L-CAPZA1-MOV10, FIGN-GRB14, and TBX5-TBX3) had 464 
evidence of a second independent signal in the region in EUR_SAS samples with a common variant 465 
(Pconditional<1x10
-4; Supplementary Table 15) that has not been previously reported.   466 
Having identified 30 novel loci associated with BP traits, as well as additional new independent SNVs at 467 
four novel loci and five known loci, we calculated the percent of the trait variance explained (Methods). 468 
This was 2.08%/2.11%/1.15% for SBP/DBP/PP for the 43 previously reported BP-SNVs covered in our 469 
dataset, increasing to 3.38%/3.41%/2.08% respectively with the inclusion of the 30 lead SNVs from novel 470 
loci, plus new independent SNV-BP associations identified from novel and known loci. 471 
 472 
Effect of BP SNVs on cardiovascular traits & risk factors 473 
Amongst our novel BP-SNV associations, some have previously been reported to be associated with other 474 
cardiovascular traits and risk factors (Supplementary Table 16); these include coronary heart disease (CHD: 475 
PHACTR1, ABO)20,21, QT interval (RNF207)22, heart rate (MYH6)23, and cholesterol levels (2q36.3, ABO, 476 
ZNF101)24. 477 
To test the impact of BP variants on cardiovascular endpoints and risk factors we created three weighted 478 
genetic risk scores (GRS) according to SBP/DBP/PP based on the newly identified and previously published 479 
BP variants (up to N=125; Methods). The GRS models were used to test the causal effect of BP on the 480 
following traits: ischemic stroke (including the subtypes, cardiometabolic, large and small vessel 25), CHD, 481 
heart failure,26 left ventricular mass27, left ventricular wall thickness27, high-density lipoprotein cholesterol 482 
(HDL-c), low-density lipoprotein (LDL-c), triglycerides, total cholesterol, body mass index (BMI), waist-483 
hip ratio adjusted BMI, height and estimated glomerular filtration rate (eGFR) (Methods). As expected, BP 484 
was positively associated with increased CHD risk (OR [95% CI]=1.39[1.22-1.59] per 10mmHg increase in 485 
SBP, P=6.07×10-7; 1.62[1.28-2.05] per 10mmHg increase in DBP, P=5.99x10-5; 1.70[1.34-2.16] per 486 
10mmHg increase in PP, P=1.20x10-5; Table 3), and increased risk of ischemic stroke (OR [95% 487 
CI]=1.93[1.47-2.55] per 10mmHg increase in DBP, P=2.81×10-6; 1.57[1.35-1.84] per 10mmHg increase in 488 
SBP, P=1.16×10-8; 2.12[1.58-2.84] per 10mmHg increase in PP, P=5.35x10-7). The positive association with 489 
ischemic stroke was primarily due to large vessel stroke (Table 3).  DBP and SBP were also positively 490 
associated with left ventricular mass (9.57 [3.98-15.17] gram increase per 10mmHg increase in DBP, 491 
P=8.02x10-4 and 5.13 [1.77-8.48] gram increase per 10mmHg increase in SBP, P=0.0027) and left 492 
ventricular wall thickness (0.10 [0.06-0.13] cm increase per 10mmHg increase in DBP, P=1.88x10-8 and 493 
0.05 [0.03-0.07] cm increase per 10mmHg increase in SBP, P=5.52x10-6, Table 3). There was no convincing 494 
evidence to support the BP associated variants having an effect on lipid levels (P>0.1), BMI (P>0.005), 495 
waist hip ratio adjusted BMI (P>0.1), height (P>0.06), eGFR (P>0.02) or heart failure (P>0.04). The causal 496 
associations with CHD, stroke, and left ventricular measures augment the results from a previous association 497 
analysis using 29 BP variants28. Our data strongly support the previous observations of no causal 498 
relationship between BP and eGFR. Lack of evidence of a BP effect with heart failure may only be due to 499 
lack of power, as the association was in the expected direction.  500 
 501 
 502 
Possible functional variants at BP loci and candidate genes 503 
Twenty-six of our newly discovered BP associated SNVs had MAF≥0.05 and therefore due to extensive LD 504 
with other SNVs not genotyped on the Exome array, identifying the causal genes requires additional 505 
information. If a SNV is associated with increased or decreased expression of a particular gene, i.e. it is an 506 
expression quantitative trait locus (eQTL) this suggests the gene on which the SNV acts could be in the 507 
causal pathway. To help identify potential candidate causal genes in the novel BP loci (Supplementary Table 508 
9), information from publicly available eQTL databases was investigated (MuTHER for LCL, adipose and 509 
skin and GTEx for nine tissues including the heart and tibial artery; Methods). 510 
The DBP increasing allele of the nsSNV, rs7302981-A, was associated with increased expression of CERS5 511 
in: LCLs (PMuTHER=3.13x10
-72) skin (PMuTHER=2.40x10
-58) adipose (PMuTHER=2.87x10
-54) and nerve 512 
(PGTEx=4.5x10
-12) (Supplementary Figure 4). Additional testing (Methods) provided no evidence against 513 
colocalisation of the eQTL and DBP association signals, implicating CERS5 as a candidate causal gene for 514 
this DBP locus. CERS5 (LAG1 homolog, ceramide synthase 5) is involved in the synthesis of ceramide, a 515 
lipid molecule involved in several cellular signaling pathways. Cers5 knockdown has been shown to reduce 516 
cardiomyocyte hypertrophy in mouse models29. However, it is unclear whether the blood pressure raising 517 
effects at this locus are the cause or result of any potential effects on cardiac hypertrophy. Future studies 518 
investigating this locus in relation to parameters of cardiac hypertrophy and function (e.g. ventricular wall 519 
thickness) should help address this question. 520 
The DBP raising allele of the nsSNV (rs867186-A) was associated with increased expression of PROCR in 521 
adipose tissue (PMuTHER=3.24x10
-15) and skin (PMuTHER=1.01x10
-11) (Supplementary Figure 4). There was no 522 
evidence against colocalisation of the eQTL and DBP association thus supporting PROCR as a candidate 523 
causal gene. PROCR encodes the Endothelial Protein C receptor, a serine protease involved in the blood 524 
coagulation pathway, and rs867186 has previously been associated with coagulation and haematological 525 
factors.30,31 The PP decreasing allele of, rs10407022-T, which is predicted to have detrimental effects on 526 
protein structure (Methods) was associated with increased expression of AMH in muscle (PGTEx=9.95x10
-15), 527 
thyroid (PGTEx=8.54x10
-7), nerve (PGTEx=7.15x10
-8), tibial artery (PGTEx=6.46x10
-9), adipose 528 
(PGTEx=4.69x10
-7), and skin (PGTEx=5.88x10
-8) (Supplementary Figure 4). There was no evidence against 529 
colocalisation of the eQTL and PP association, which supports AMH as a candidate causal gene for PP. Low 530 
AMH levels have been previously associated with hypertensive status in women with the protein acting as a 531 
marker of ovarian reserve32. The intergenic SBP raising allele of rs4728142-A was associated with reduced 532 
expression of IRF5 in skin (PMuTHER=5.24x10
-31) and LCLs (PMuTHER=1.39x10
-34), whole blood 533 
(PGTEx=3.12x10
-7) and tibial artery (PGTEx=1.71x10
-7).  534 
 535 
Three novel rare nsSNVs were identified that map to RBM47, RRAS (both associated with SBP) and 536 
COL21A1 (associated with PP). They had larger effect sizes than common variant associations (>1.5mmHg 537 
per allele; Supplementary Figure 5) and were predicted to have detrimental effects on protein structure 538 
(Supplementary Table 16; Methods). In RBM47, rs35529250 (p.Gly538Arg) is located in a highly conserved 539 
region of the gene and was most strongly associated with SBP (MAF=0.008; +1.59 mmHg per T allele; 540 
P=5.90x10-9). RBM47 encodes the RNA binding motif protein 47 and is responsible for post-transcriptional 541 
regulation of RNA, through its direct and selective binding with the molecule.33 In RRAS, rs61760904 542 
(p.Asp133Asn) was most strongly associated with SBP (MAF=0.007; +1.51 mmHg per T allele; P=8.45x10-543 
8). RRAS encodes a small GTPase belonging to the Ras subfamily of proteins H-RAS, N-RAS, and K-RAS 544 
and has been implicated in actin cytoskeleton remodelling, and controlling cell proliferation, migration and 545 
cycle processes34. The nsSNV in COL21A1 (rs200999181, p.Gly665Val) was most strongly associated with 546 
PP (MAF=0.001; +3.14 mmHg per A allele; P=1.93x10-9). COL21A1 encodes the collagen alpha-1 chain 547 
precursor of type XXI collagen, a member of the FACIT (fibril-associated collagens with an interrupted 548 
triple helix) family of proteins35. The gene is detected in many tissues, including the heart and aorta. Based 549 
on our results, these three genes represent good candidates for functional follow-up. However, due to the 550 
incomplete coverage of all SNVs across the region on the Exome chip, it is possible that other non-551 
genotyped SNVs may better explain some of these associations. We therefore checked for variants in LD 552 
(r2>0.3) with these three rare nsSNVs in the UK10K + 1000G dataset36 to ascertain if there are other 553 
candidate SNVs at these loci (Supplementary Table 17). There were no SNVs within 1Mb of the RBM47 554 
locus in LD with the BP associated SNV. At the COL21A1 locus there were only SNVs in moderate LD, and 555 
these were annotated as intronic, intergenic or in the 5’UTR. At the RRAS locus, there were two SNVs in 556 
strong LD with the BP associated SNV, which both mapped to introns of SCAF1 and are not predicted to be 557 
damaging. All SNVs in LD at both loci were rare as expected (Supplementary Table 17) supporting a role 558 
for rare variants. Hence, the rare BP associated nsSNVs at RBM47, COL21A1 and RRAS remain the best 559 
causal candidates. 560 
 561 
Pathway and network analyses 562 
To identify connected gene sets and pathways implicated by the BP associated genes we used Meta-Analysis 563 
Gene-set Enrichment of variant Associations (MAGENTA)37 and GeneGo MetaCore (Thomson Reuters, 564 
UK).  MAGENTA tests for over-representation of BP associated genes in pre-annotated pathways (gene 565 
sets) (Methods and Supplementary Table 18a). GeneGo Metacore identifies potential gene networks.  The 566 
MAGENTA analysis was used for hypothesis generation and results were compared with the GeneGo 567 
Metacore outputs to cross-validate findings. 568 
Using MAGENTA there was an enrichment (P<0.01 and FDR<5% in either the EUR_SAS or the EUR 569 
participants) of six gene sets with DBP, three gene sets with HTN and two gene sets for SBP 570 
(Supplementary Table 18b).  The RNA polymerase I promoter clearance (chromatin modification) pathway 571 
showed the most evidence of enrichment with genes associated with DBP (PReactome=8.4x10
-5, FDR=2.48%). 572 
NOTCH signalling was the most associated pathway with SBP (PReactome = 3.00x10
-4, FDR = 5%) driven by 573 
associations at the FURIN gene.  The inorganic cation anion solute carrier (SLC) transporter pathway had 574 
the most evidence of enrichment by HTN associated genes (PReactome=8.00x10
-6, FDR=2.13%).  575 
Using GeneGo MetaCore, five network processes were enriched (FDR<5%; Methods; Supplementary 576 
Tables 19 and 20). These included several networks with genes known to influence vascular tone and BP: 577 
inflammation signalling, P=1.14x10-4 and blood vessel development P=2.34x10-4. The transcription and 578 
chromatin modification network (P=2.85x10-4) was also enriched, a pathway that was also highlighted in the 579 
MAGENTA analysis, with overlap of the same histone genes (HIST1H4C, HIST1H2AC, HIST1H2BC, 580 
HIST1H1T) and has also been recently reported in an integrative network analysis of published BP loci and 581 
whole blood expression profiling38. Two cardiac development pathways were enriched: the oxidative stress-582 
driven (ROS/NADPH) (P=4.12x10-4) and the Wnt/β-catenin/integrin-driven (P=0.0010). Both these cardiac 583 
development pathways include the MYH6, MYH7, and TBX2 genes, revealing a potential overlap with 584 
cardiomyopathies and hypertension, and suggesting some similarity in the underlying biological 585 
mechanisms. 586 
 587 
Discussion 588 
By conducting the largest ever genetic study of BP, we identified further novel common variants with small 589 
effects on BP traits, similar to what has been observed for obesity and height39,40. More importantly, our 590 
study identified some of the first rare coding variants of strong effect (>1.5mmHg) that are robustly 591 
associated with BP traits in the general population, complementing and extending the previous discovery 592 
and characterisation of variants underlying rare Mendelian disorders of blood pressure regulation 41. Using 593 
SNV associations in 17 genes reported to be associated with monogenic disorders of blood pressure 594 
(Methods) we found no convincing evidence of enrichment (Penrichment=0.044). This suggests that BP control 595 
in the general population may occur through different pathways to monogenic disorders of BP re-enforcing 596 
the importance of our study findings. The identification of 30 novel BP loci plus further new independent 597 
secondary signals within four novel and five known loci (Methods) has augmented the trait variance 598 
explained by 1.3%, 1.2% and 0.93% for SBP, DBP and PP respectively within our data-set. This suggests 599 
that with substantially larger sample sizes, for example through UK BioBank42, we expect to identify 1000s 600 
more loci associated with BP traits, and replicate more of our discovery SNV associations that are not yet 601 
validated in the current report.  602 
The discovery of rare missense variants has implicated several interesting candidate genes, which are often 603 
difficult to identify from common variant GWAS, and should therefore lead to more rapidly actionable 604 
biology. A2ML1, COL21A1, RRAS and RBM47 all warrant further follow-up studies to define the role of 605 
these genes in regulation of BP traits, as well as functional studies to understand their mechanisms of action. 606 
COL21A1 and RRAS warrant particular interest since both are involved in blood vessel remodelling, a 607 
pathway of known aetiological relevance to hypertension.  608 
We observed a rare nonsense SBP associated variant in ENPEP (rs33966350; p.Trp317* ): this overlaps a 609 
highly conserved region of both the gene and protein and is predicted to result in either a truncated protein 610 
with reduced catalytic function or is subject to nonsense mediated RNA decay.  ENPEP converts angiotensin 611 
II (AngII) to Ang-III.  AngII activates the angiotensin 1 (AT1) receptor resulting in vasoconstriction, while 612 
AngIII activates the angiotensin 2 (AT2) receptor that promotes vasodilation and protects against 613 
hypertension.43 The predicted truncated protein may lead to predominant AngII signaling in the body, and 614 
increases in BP.  This new observation could potentially inform therapeutic strategies. Of note, angiotensin-615 
converting-enzyme (ACE) inhibitors are commonly used in the treatment of hypertension. However, patients 616 
who suffer from adverse reactions to ACE inhibitors, such as dry cough and skin rash, would benefit from 617 
alternative drugs that target RAAS. Murine studies have shown that in the brain, AngIII is the preferred AT1 618 
agonist that promotes vasoconstriction and increases blood pressure, as opposed to AngII in the peripheral 619 
system. These results have motivated the development of brain specific APA inhibitors to treat 620 
hypertension44. Our results confirm APAs, such as ENPEP, as a valid target to modify blood pressure, but 621 
suggest that long-term systemic reduction in APA activity may lead to an increase in blood pressure. Future 622 
studies are needed to examine the effects of the p.Trp317* variant on the RAAS system, specifically in the 623 
brain and peripheral vasculature, in order to test the benefits of the proposed therapeutic strategy in humans.  624 
In addition to highlighting new genes in pathways of established relevance to BP and hypertension, and 625 
identifying new pathways, we have also identified multiple signals at new loci. For example, there are three 626 
distinct signals at the locus containing the MYH6/MYH7 genes, and we note that TBX2 maps to one of the 627 
novel regions. These genes are related to cardiac development and/or cardiomyopathies, and provide an 628 
insight into the shared inheritance of multiple complex traits. Unravelling the causal networks within these 629 
polygenic pathways may provide opportunities for novel therapies to treat or prevent both hypertension and 630 
cardiomyopathies. 631 
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RR, JT, MU. Study Phenotyping in alphabetical order by consortium (CHD Exome+, ExomeBP and 999 
GoT2D): PA, DA, SBl, MC, JF, JWJ, FKe, KK, SFN, BGN, CJP, AR, MS, NSa, JV, WZo, RAB, MJB, 1000 
MJC, JCC, JMC, AFD, ASFD, LAD, TE, AF, GG, GH, PH, AS H, OLH, EI, MJ, FK, JSK, LLi, LLa, GM, 1001 
AMc, PM, AMe, RMg, MJN, MEN, OPo, NP, FR, VS, NJS, TDS, AVS, JMS, MT, AV, NV, NJW, TiT, 1002 
CC, LLH, MEJ, AK, PK, JL DPS, SM, ERBP, AS, TS, HMS, BT. Study Data QC and analysis in 1003 
alphabetical order by consortium (CHD Exome+, ExomeBP and GoT2D): ASB, AJMC, JMMH, JK, 1004 
SFN, BGN, MMN, SP, MP, PSu, ST, GV, SMW, RY, FWA, JPC, FD, AF, TF, CH, AMc, AMj, APM, 1005 
PBM, CP, WR, FR, NJS, MT, VT, HW, HY, NG, AKM, XS.  Exome chip data QC in alphabetical order 1006 
by consortium (CHD Exome+, ExomeBP and GoT2D): ASB, JMMH, SFN, BGN, PSu, RY, FWA, 1007 
PIWB, AIFB, JCC, JPC, PD, LAD, FD, EE, CF, TF, SEH, PH, SSH, KH, JEH, EK, AMj, GM, JM, NM, 1008 
EMi, AMo, APM, PBM, CPN, MJN, CP, AP, WR, NRR, RAS, NS, LS, KES, MDT, VT, TVV, TVV, NV, 1009 
HW, HY, AMY, EZ, WZg, NG, CML, AKM, XS. Exome chip Data analysis in alphabetical order by 1010 
consortium (CHD Exome+, ExomeBP and GoT2D): JMMH, PSu, RY, FWA, PIWB, AIFB, RAB, MJC, 1011 
JCC, JPC, PD, LAD, PE, EE, CF, TF, PWF, SF, CG, SEH, PH, ASH, CH, OLH, JEH, EI, MJ, FKa, JSK, 1012 
DCML, LLi, JL, GM, RMr, JM, NM, MIM, PM, OM, CM, EMi, AMo, APM, RMg, PBM, CPN, MJN, TO, 1013 
APo, APa, WR, NRR, NJS, RAS, NS, LS, TDS, KES, MDT, ET, VT, TVV, NV, LVW, NJW, HW, HY, 1014 
AMY, EZ, HZ, WZg, LLB, APG, NG, MHs, JRH, AUJ, JBJ, CML, AKM, NN, XS, AS, AJS. GRS 1015 
lookups: AEJ, EMa, HFM, HL, HMH, JFF, MTr, RSV, WL.  1016 
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1136 
Figure Legends 1137 
Figure 1 Study design and work flow diagram of single variant discovery analyses. EUR=European, SAS=South 1138 
Asian, HIS=Hispanic, AA=African American, HTN=hypertension, BP=blood pressure, SBP=systolic blood pressure, 1139 
DBP= diastolic blood pressure, PP=pulse pressure, N=sample size, MAF=minor allele frequency, P=P-value 1140 
significance threshold, SNV=single-nucleotide variant, GWS=genome-wide significance *Further details of the selection 1141 
criteria are provided in the methods. 1142 
Figure 2 Discovery SNV-BP associations.  Results are provided for (a) transformed SBP (b) transformed DBP (c) 1143 
transformed PP and (d) HTN in the European and South Asian (EUR_SAS) discovery samples. The y-axis represents –1144 
log10P for association. Red triangles represent variants that map to one of the 81 regions selected for replication, blue 1145 
triangles represent SNVs that map to previously published BP regions, and grey triangles represent all remaining SNVs. 1146 
SNVs are ordered according to chromosome (black lines on the outside of the plot) and physical position. Genes that 1147 
SNVs map to are given in the outer blocks. 1148 
 1149 
Figure 3 Overlap of the 30 novel loci associations across SBP, DBP, PP and HTN. The Venn diagram shows which 1150 
of the 30 newly identified BP loci are associated with multiple BP traits. Only SNV-BP trait associations that were 1151 
genome-wide significant (P < 5x10-8) in the combined discovery and replication meta-analyses are listed for any given 1152 
BP trait, within the corresponding ancestry dataset that the given locus was validated for (see Tables 1 and 2). The 1153 
association of RRAS variant with SBP was replicated in the independent samples, but did not achieve GWS in the 1154 
combined discovery and replication meta-analysis and is therefore only included for SBP. HTN=hypertension, 1155 
SBP=systolic blood pressure, DBP= diastolic blood pressure, PP=pulse pressure. 1156 
Figure 4 Study design for conditional analyses and rare variant gene-based discovery analyses. 1157 
RMW=RareMetalWorker, EUR=European, SAS = South Asian, HTN=hypertension, BP=blood pressure, SBP=systolic 1158 
blood pressure, DBP= diastolic blood pressure, PP=pulse pressure. N=sample size, MAF=minor allele frequency, P=P-1159 
value significance threshold, Pcond=conditional P-value significance threshold 1160 
Figure 5 Locus plot for A2ML1 and secondary amino acid structure of the gene product. (a) Locus plot for A2ML1 1161 
associated with HTN identified through gene based tests. The variants’ positions along the gene (x axis, based on 1162 
human genome build 37) and the –log10(P-value of association) (y axis) are indicated. The variants are colour coded: 1163 
nonsense (black), missense, predicted damaging (blue), and missense (orange). The schematic above the x-axis 1164 
represents the intron / exon (black vertical bars) structure, the untranslated regions are shown as grey vertical bars. 1165 
(b) The white box denotes the full-length amino acid sequence for each of the two gene products. Black numbers 1166 
denote amino acid residue positions of note. Coloured boxes depict putative functional domains (see below). Coloured 1167 
vertical lines indicate the amino acid substitutions corresponding to the variants depicted in the locus plots above using 1168 
the same colour coding. Bold, italic indicates the SNV association with smallest P-value. 1169 
Dark grey – signal peptide sequence. Brown – regions of intramolecular disulfide bonds. For simplicity only those 1170 
regions coinciding with variants described were indicated. Black – bait region described to interact with proteases. 1171 
Purple – thiol ester sequence region aiding in interaction with proteases. Light grey – alpha helical regions thought to 1172 
mediate A2ML1 interaction with LRP1, facilitating receptor-mediated endocytosis. 1173 
 1174 
 1175 
  1176 
Table 1 Novel blood pressure trait associated loci. Variants with formal replication 1177 
Variant information  Discovery Replication Combined 
Locus rsID Chr:Pos (EA:EAF) Trait Pt PU N β P N β P 
EUR 
RNF207 rs709209 1:6.28 (A:0.655) PP 4.57 x 10
-6 1.60 x 10-6 122,780 0.17 5.83 x 10-4 284,683 0.20 9.62 x 10-9 
C5orf56 rs12521868 5:131.78 (T:0.373) DBP 1.59 x 10
-6 3.03 x 10-7 122,795 -0.18 2.29 x 10-5 282,023 -0.19 6.12 x 10-11 
PHACTR1 rs9349379 6:12.90 (A:0.566) SBP 2.11 x 10-8 1.78 x 10-7 122,809 0.24 4.06 x 10-4 284,673 0.29 8.84 x 10-10 
COL21A1 rs200999181† 6:55.94 (A:0.002) PP 3.08 x 10
-8 2.46 x 10-7 121,487 2.70 1.90 x 10-4 242,486 3.25 6.27 x 10-10 
ABO rs687621 9:136.14 (A:0.615) DBP 8.80 x 10
-8 2.55 x 10-7 122,798 0.16 1.96 x 10-4 276,014 0.19 5.45 x 10-10 
ADO rs10995311 10:64.56 (C:0.567) DBP 1.86 x 10
-6 1.14 x 10-6 122,798 0.23 8.47 x 10-8 266,456 0.21 1.12 x 10-12 
LMO1 rs110419 11:8.25 (A:0.48) DBP 9.41 x 10
-6 2.22 x 10-5 122,798 0.16 1.81 x 10-4 279,935 0.16 3.04 x 10-8 
OR5B12 rs11229457 11:58.21 (T:0.236) SBP 1.58 x 10
-6 4.62 x 10-5 122,809 -0.32 7.53 x 10-5 284,680 -0.31 2.70 x 10-8 
CERS5 rs7302981 12:50.54 (A:0.361) DBP 1.35 x 10
-13 4.60 x 10-11 122,798 0.24 2.64 x 10-8 284,718 0.25 1.38 x 10-17 
MYH6 rs452036 14:23.87 (A:0.327) PP 4.59 x 10
-11 2.80 x 10-13 122,780 -0.21 1.81 x 10-5 284,672 -0.28 2.96 x 10-16 
DPEP1 rs1126464 16:89.70 (C:0.256) DBP 1.19 x 10
-9 4.35 x 10-11 118,677 0.24 1.68 x 10-6 261,564 0.28 1.02 x 10-15 
TBX2 rs8068318† 17:59.48 (T:0.698) DBP 7.46 x 10
-13 5.71 x 10-10 122,798 0.26 3.23 x 10-8 281,978 0.26 1.95 x 10-16 
RGL3 rs167479 
19:11.53 (T:0.486) 
DBP 
2.22 x 10-23 1.97 x 10-22 
122,797 -0.29 
3.01 x 10-
11 
283,332 -0.33 1.99 x 10-31 
PREX1 rs6095241 20:47.31 (A:0.452) DBP 5.65 x 10
-6 2.29 x 10-5 122,798 -0.18 2.56 x 10-5 281,322 -0.17 4.75 x 10-9 
ALL ancestry 
RBM47 rs35529250† 4:40.43 (T:0.01) SBP 6.56 x 10
-7 6.15 x 10-6 148,878 -1.43 5.02 x 10-4 306,352 -1.55 2.42 x 10-8 
OBFC1 rs4387287 10:105.68 (A:0.157) SBP 2.23 x 10
-8 1.32 x 10-7 147,791 0.28 3.37 x 10-4 320,494 0.36 9.12 x 10-10 
RRAS rs61760904† 19:50.14 (T:0.008) SBP 1.96 x 10
-6 1.90 x 10-5 148,878 1.38 5.70 x 10-4 322,664 1.50 8.45 x 10-8 
SNV-BP associations are reported for the newly identified BP loci that replicated at P < 6.2 x 10-4 (Bonferroni correction for the 81 variants selected for replication for a primary 1178 
blood pressure trait; Methods). Loci are categorised into EUR and ALL ancestry based on the meta-analysis used to replicate the variants for the primary BP trait shown in columns 1179 
labelled ‘Trait’. In the columns that contains the discovery meta-analyses results, Pt represents the P-value for association of the variant with the transformed primary BP trait in the 1180 
EUR_SAS discovery meta-analyses (which was also used to select the variant for replication) and Pu  represents the P-value for association with the untransformed primary BP trait 1181 
in the ancestry in which the variant replicated. N, β and P, which denote the number of samples, estimated allelic effect and P-value for association with the primary BP trait, are 1182 
provided for the untransformed primary BP trait in the replication data and also from the combined (discovery and replication) meta-analyses. NB: ALL ancestry corresponds to all 1183 
ancestries in the combined (discovery + replication) meta-analyses 1184 
Locus – Gene or region containing the SNV, rsID - dbSNP rsID. Chr:Pos (EA:EAF) – Chromosome:NCBI Build 37 position in Mb (effect allele:effect allele frequency), Trait – primary 1185 
blood pressure trait for which the variant was and also replicated, β - effect estimate, N:sample size, EUR - European.  1186 
† indicates it is a non-synonymous SNV (nsSNV) or is in linkage disequilibrium with a nsSNV (r2 > 0.8) that is predicted to be damaging   1187 
Table 2 Novel blood pressure trait associated loci. Variants with GWS evidence of association in combined 1188 
meta-analyses 1189 
 1190 
Variant information  Discovery Replication Combined 
Locus rsID Chr:Pos (EA:EAF) Trait Pt PU N β P N β P 
EUR 
2q36.3 rs2972146 2:227.10 (T:0.652) DBP§ 
(HTN) 
1.51 x 10-9 2.47 x 10-7 122,798 0.13 2.20 x 10-3 275,610 0.17 8.40 x 10-9 
ZBTB38 rs16851397 3:141.13 (A:0.953) DBP§ 
(SBP) 
6.87 x 10-6 3.20 x 10-5 122,798 -0.38 1.20 x 10-4 284,717 -0.38 3.01 x 10-8 
PRDM6 rs1008058 5:122.44 (A:0.135) SBP 5.09 x 10-7 1.01 x 10-8 43,109 0.46 3.61 x 10-3 176,362 0.55 2.99 x 10-10 
GPR20 rs34591516 8:142.37 (T:0.055) SBP§ 
(DBP) 
1.54 x 10-6 1.01 x 10-7 122,807 0.51 4.20 x 10-4 282,009 0.64 6.10 x 10-10 
HOXB7 rs7406910 17:46.69 (T:0.118) SBP 6.07 x 10-10 2.74 x 10-9 122,809 -0.20 4.89 x 10-2 284,690 -0.46 3.80 x 10-8 
AMH rs10407022† 19:2.25 (T:0.82) PP 1.63 x 10-7 1.73 x 10-7 118,656 -0.19 1.62 x 10-3 252,525 -0.26 5.94 x 10-9 
ZNF101 rs2304130 19:19.79 (A:0.914) DBP 1.66 x 10-8 1.92 x 10-8 122,798 -0.17 1.71 x 10-2 284,705 -0.29 1.53 x 10-8 
PROCR rs867186 20:33.76 (A:0.873) DBP 1.44 x 10-6 4.15 x 10-7 122,798 0.21 2.48 x 10-3 284,722 0.26 1.19 x 10-8 
RRP1B rs9306160 21:45.11 (T:0.374) DBP§ 
(SBP) 
1.04 x 10-8 1.90 x 10-6 100,489 -0.16 4.30 x 10-4 249,817 -0.18 6.80 x 10-9 
TNRC6B rs470113 22:40.73 (A:0.804) PP 1.48 x 10-10 1.31 x 10-9 122,780 -0.14 1.37 x 10-2 284,683 -0.25 1.67 x 10-9 
ALL ancestry 
7q32.1 rs4728142 7:128.57 (A:0.433) SBP 8.10 x 10-6 4.21 x 10-6 150,542 -0.21 8.62 x 10-4 338,338 -0.24 3.45 x 10-8 
PRKAG1 rs1126930† 12:49.40 (C:0.036) PP 2.12 x 10-6 4.62 x 10-7 151,481 0.36 3.74 x 10-3 314,894 0.50 3.34 x 10-8 
SBNO1 rs1060105 12:123.81 (T:0.209) DBP 6.66 x 10-7 1.09 x 10-6 150,532 -0.15 2.67 x 10-3 336,413 -0.18 3.07 x 10-8 
 1191 
SNV-BP associations are reported for the newly identified BP loci that showed genome-wide significant association (P < 5 x 10-8) in the combined discovery and replication meta-1192 
analyses. In the columns that contain results from the discovery meta-analyses, Pt represents the P-value for association of the variant with the transformed primary BP trait in the 1193 
EUR_SAS discovery meta-analyses (used to select the variant for replication) and Pu represents the P-value for association with the untransformed BP trait in the ancestry in which 1194 
the variant was validated.  Loci are categorised into EUR and ALL ancestry based on the ancestry in which the variant showed association with a blood pressure trait at P < 5 x 10-8. 1195 
N, β and P, which denote the number of samples, estimated allelic effect and P-value for association with the validated BP trait, are provided for the untransformed BP trait in the 1196 
replication data and also from the combined (discovery and replication) meta-analyses. NB: ALL ancestry corresponds to all ancestries in the combined (discovery + replication) 1197 
meta-analyses.  1198 
 1199 
Locus – Gene or region containing the SNV, rsID - dbSNP rsID. Chr:Pos (EA:EAF) – Chromosome:NCBI Build 37 position in Mb (effect allele:effect allele frequency), Trait - blood 1200 
pressure trait for which association is reported, EUR - European.  1201 
§ At four loci (2q36.3, ZBTB38, GPR20 and RRP1B) the primary trait used to select the variants for replication is given in parentheses because the variant associations were 1202 
validated in the combined meta-analysis for the listed secondary trait. For these variants, Pt denotes the P-value for association with the primary trait, the other P-values provided 1203 
are for the secondary trait.  1204 
† indicates it is a non-synonymous SNV (nsSNV) or is linkage disequilibrium with a nsSNV (r2>0.8) that is predicted to be damaging1205 
Table 3 Results of the genetic risk score analyses across CVD traits and risk factors. 1206 
CHD, coronary heart disease; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate; DBP, diastolic blood pressure; SBP systolic blood pressure; PP, pulse pressure; OR, odds ratio; g, grams; INVT, inverse normally 1207 
transformed (hence no units); N, sample size; P, P-value of association of BP with the trait listed; CI, confidence interval. Results are considered significant if P < 0.0038, which corresponds to a Bonferroni correction for 13 phenotypes tested.1208 
Outcome Units N DBP (per 10mmHg increase) SBP (per 10mmHg increase) PP (per 10mmHg increase) 
   Effect [95% CI] P Effect [95% CI] P Effect [95% CI] P 
CHD OR 82,056  1.62 [ 1.28, 2.05] 5.99 x 10-5  1.39 [ 1.22, 1.59] 6.07 x 10-7  1.70 [ 1.34, 2.16] 1.20 x 10-5 
Ischemic stroke OR 25,799  1.93 [ 1.47, 2.55] 2.81 x 10-6  1.57 [ 1.35, 1.84] 1.16 x 10-8  2.12 [ 1.58, 2.84] 5.35 x 10-7 
Cardioembolic stroke OR 16,113  1.43 [ 0.86, 2.39] 0.1683  1.33 [ 0.99, 1.80] 0.0584  1.73 [ 1.00, 3.02] 0.0518 
Large vessel stroke OR 13,903  2.26 [ 1.25, 4.08] 0.0068  1.85 [ 1.32, 2.59] 3.61 x 10-4  3.05 [ 1.64, 5.68] 4.37 x 10-4 
Small vessel stroke OR 15,617  1.96 [ 1.13, 3.41] 0.0168  1.56 [ 1.13, 2.16] 0.0064  1.98 [ 1.09, 3.61] 0.0248 
Heart failure OR 13,282  1.48 [ 1.02, 2.17] 0.0409  1.25 [ 1.00, 1.57] 0.0512  1.33 [ 0.88, 2.02] 0.1757 
Left ventricular mass g 11,273  9.57 [ 3.98,15.17] 8.02 x 10-4  5.13 [ 1.77, 8.48] 0.0027  5.97 [-0.38,12.31] 0.0653 
Left ventricular wall thickness cm 11,311  0.10 [ 0.06, 0.13] 1.88 x 10-8  0.05 [ 0.03, 0.07] 5.52 x 10-6  0.05 [ 0.01, 0.09] 0.0187 
HDL mg/dl 80,395  0.25 [-1.00, 1.51] 0.6930  0.21 [-0.50, 0.92] 0.5622  0.47 [-0.79, 1.73] 0.4668 
LDL mg/dl 77,021 -1.57 [-5.20, 2.06] 0.3972  0.07 [-2.03, 2.16] 0.9498  1.87 [-1.86, 5.59] 0.3255 
Total cholesterol mg/dl 80,455 -1.34 [-5.90, 3.22] 0.5639  0.70 [-1.93, 3.32] 0.6029  3.68 [-0.97, 8.33] 0.1209 
Triglycerides mg/dl 77,779  0.02 [-0.03, 0.08] 0.3859  0.02 [-0.01, 0.05] 0.2697  0.03 [-0.03, 0.08] 0.3025 
BMI INVT 526,508 -0.10 [-0.18,-0.01] 0.0342 -0.07 [-0.13,-0.02] 0.0058 -0.12 [-0.23,-0.02] 0.0165 
WHRadjBMI INVT 344,369  0.03 [-0.04, 0.11] 0.4025  0.03 [-0.02, 0.08] 0.2170  0.06 [-0.03, 0.15] 0.1885 
Height INVT 458,927  0.02 [-0.15, 0.18] 0.8592 -0.04 [-0.15, 0.06] 0.4170 -0.18 [-0.37, 0.01] 0.0683 
eGFR INVT 51,039 -0.02 [-0.15, 0.11] 0.7810 -0.03 [-0.10, 0.04] 0.4080 -0.07 [-0.20, 0.06] 0.2741 
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1210 
Online Methods 1211 
Overview of discovery studies 1212 
The cohorts contributing to the discovery meta-analyses comprise studies from three consortia (CHD 1213 
Exome+, ExomeBP, and GoT2D/T2D-GENES) with a total number of 192,763 unique samples.  All 1214 
participants provided written informed consent and the studies were approved by their local Research Ethics 1215 
Committees and/or Institutional Review Boards.  1216 
The CHD Exome+ consortium comprised 77,385 samples: eight studies (49,898 samples) of European 1217 
(EUR) ancestry, two studies (27,487 samples) of South Asian (SAS) ancestry (Supplementary Table 1). The 1218 
ExomeBP consortium included 25 studies (75,620 samples) of EUR ancestry (Supplementary Table 1).  The 1219 
GoT2D consortium comprised 14 studies (39,758 samples) of Northern EUR ancestry from Denmark, 1220 
Finland, and Sweden (Supplementary Table 1). The participating studies and their characteristics including 1221 
BP phenotypes are detailed in Supplementary Tables 1 and 2. Note, any studies contributing to multiple 1222 
consortia were only included once in all meta-analyses.  1223 
Phenotypes 1224 
Four blood pressure (BP) traits were analysed: systolic blood pressure (SBP), diastolic blood pressure 1225 
(DBP), pulse pressure (PP) and hypertension (HTN).  For individuals known to be taking BP lowering 1226 
medication, 15/10 mmHg was added to the raw SBP/DBP values, respectively, to obtain medication-1227 
adjusted SBP/DBP values45.  PP was defined as SBP minus DBP, post-adjustment.  For HTN, individuals 1228 
were classified as hypertensive cases if they satisfied at least one of: (i) SBP≥140 mmHg, (ii) DBP≥90 1229 
mmHg, (iii) taking anti-hypertensive or BP lowering medication. All other individuals were included as 1230 
controls. The four BP traits were correlated (SBP:DBP correlations were between 0.6 and 0.8, and SBP:PP 1231 
correlations were ~0.8). However, they measure partly distinct physiological features including, cardiac 1232 
output, vascular resistance, and arterial stiffness, all measures for determining a cardiovascular risk profile. 1233 
Therefore the genetic architecture of the individual phenotypes are of interest, and a multi-phenotype 1234 
mapping approach was not adopted. 1235 
 1236 
 1237 
Genotyping 1238 
All samples were genotyped using one of the Illumina HumanExome Beadchip arrays (Supplementary Table 1239 
3). An Exome chip quality control Standard Operating Procedure (SOP) developed by Anubha Mahajan, 1240 
Neil Robertson and Will Rayner at the Wellcome Trust Centre for Human Genetics, University of Oxford 1241 
was used by most studies for genotype calling and QC46 (Supplementary Table 3). All genotypes were 1242 
aligned to the plus strand of the human genome reference sequence (Build37) prior to any analyses and any 1243 
unresolved mappings were removed. Genotype cluster plots were reviewed for all the novel rare variants 1244 
(both lead and secondary signals) and for rare variants that contributed to the gene-based testing. 1245 
Meta-analyses 1246 
Meta-analyses were performed using METAL47, for both discovery and replication analyses, using inverse 1247 
variance weighted fixed effect meta-analysis for the continuous traits (SBP, DBP and PP) and sample size 1248 
weighted meta-analysis for the binary trait (HTN). 1249 
Discovery SNV analyses 1250 
Analyses of both untransformed and inverse normal transformed SBP, DBP and PP were conducted within 1251 
each contributing study. The analyses of the transformed traits were performed in order to minimise 1252 
sensitivity to deviations from normality in the analysis of rare variants and for discovery of new SNV-BP 1253 
associations. The residuals from the null model obtained after regressing the medication-adjusted trait on the 1254 
covariates (age, age2, sex, BMI, and disease status for CHD) within a linear regression model, were ranked 1255 
and inverse normalised. These normalised residuals were used to test trait-SNV associations. All SNVs that 1256 
passed QC were analysed for association, without any further filtering by MAF, but a minor allele count of 1257 
10 was used for the analysis of HTN. An additive allelic effects model was assumed.  1258 
Two meta-analyses were performed for each trait, one with EUR and SAS ancestries combined (EUR_SAS) 1259 
and another for EUR ancestry alone. Contributing studies used principal components (PCs) to adjust for 1260 
population stratification. Consequently minimal inflation in the association test statistics, λ, was observed (1261 
λ=1.07 for SBP, 1.10 for DBP, 1.04 for PP and <1 for HTN in the transformed discovery meta-analysis in 1262 
EUR_SAS; λ= 1.06 for SBP, 1.09 for DBP, 1.05 for PP and <1 for HTN in the transformed discovery 1263 
meta-analysis in EUR; Supplementary Figure 6). The meta-analyses were performed independently in two 1264 
centres and results were found to be concordant between centres. Given the studies contributing to the 1265 
discovery analyses were ascertained on CHD or T2D, we tested potential systematic bias in calculated effect 1266 
estimates amongst these studies. No evidence of bias in the overall effect estimates was obtained. 1267 
The results for the transformed traits were taken forward and used to select candidate SNVs for replication. 1268 
Results (P-values) from the transformed and untransformed analyses were strongly correlated (r2>0.9).  1269 
Replication SNV analyses 1270 
SNVs associated with any of the transformed traits (SBP, DBP, PP) or HTN were annotated using the 1271 
Illumina SNV annotation file, humanexome-12v1_a_gene_annotation.txt, independently across two centres. 1272 
Given the difference in power to detect common versus low frequency and rare variant associations, two 1273 
different significance thresholds were chosen for SNV selection. For SNVs with MAF≥0.05, P≤1x10-5 was 1274 
selected, while, P≤ 1x10-4 was used for SNVs with MAF < 0.05. By choosing a significance threshold of 1275 
P<1x10-4 we maximized the opportunity to follow-up rare variants (making the assumption that any true 1276 
signals at this threshold could replicate at Bonferroni adjusted significance, P≤6.17x10-4, assuming α=0.05 1277 
for 81 SNVs). All previously published BP associated SNVs and any variants in LD with them (r2>0.2), 1278 
were removed from the list of associated SNVs as we aimed to replicate new findings only. SNVs for which 1279 
only one study contributed to the association result or showed evidence of heterogeneity (Phet<0.0001) were 1280 
removed from the list as they were likely to be an artefact. Where SNVs were associated with multiple traits, 1281 
to minimise the number of tests performed, only the trait with the smallest P-value was selected as the 1282 
primary trait in which replication was sought. Where multiple SNVs fitted these selection criteria for a 1283 
single region, only the SNV with the smallest P-value was selected. In total, 81 SNVs were selected for 1284 
validation in independent samples. These 81 SNVs had concordant association results for both transformed 1285 
and non-transformed traits. Eighty SNVs were selected from EUR_SAS results (with consistent support in 1286 
EUR), and one SNV from EUR results only. In the next step, we looked up the 81 SNV-BP associations 1287 
using data from a separate consortium, the CHARGE+ exome chip blood pressure consortium (who had 1288 
analysed untransformed SBP, DBP, PP and HTN), and UHP and Lolipop (ExomeBP consortium; 1289 
Supplementary Tables 2 and 3). The analysed residuals from CHARGE+ were approximately normally 1290 
distributed in their largest studies (Supplementary Figure 7). 1291 
Two meta-analyses of the replication datasets were performed: one of EUR samples, and a second of EUR, 1292 
African American, Hispanics and SAS ancestries (“ALL”). Replication was confirmed if P (1-tailed) < 1293 
0.05/81=6.17x10-4 and the effect (beta) was in the direction observed in discovery meta-analyses for the 1294 
selected trait. A combined meta-analysis was performed of discovery (untransformed results as only 1295 
untransformed data was available from CHARGE+ exome chip blood pressure consortium) and replication 1296 
results across the four traits to assess the overall support for each locus. For the combined meta-analyses, a 1297 
GWS threshold of, P≤5x10-8, was used to declare a SNV as novel rather than a less stringent experiment 1298 
wide threshold, as GWS is used to declare significance in GWAS and we wish to minimise the possibility of 1299 
false positive associations. (Note that GWS is equivalent to an exome-wide threshold of P≤2x10-7 adjusted 1300 
for four traits). 1301 
 1302 
Note: all validated BP-associated variants were associated at P<10-5 in the discovery dataset (for the primary 1303 
trait). Hence, we could have used the same inclusion criteria for both common and rare SNVs. Therefore the 1304 
optimal threshold to choose for future experiments may need further consideration. 1305 
Conditional analyses and gene-based tests 1306 
The RAREMETALWORKER (RMW) tool15 (version 4.13.3) that does not require individual level data to 1307 
perform conditional analyses and gene-based tests was used for conditional analyses. All studies that 1308 
contributed to the SNV discovery analyses were re-contacted and asked to run RMW. Only FENLAND, 1309 
GoDARTS, HELIC-MANOLIS, UKHLS and EPIC-InterAct were unable to run RMW, while two new 1310 
studies were included, INCIPE and NFBC1966 (Supplementary Table 1 and 2). In total, 43 studies (147,402 1311 
samples) were included in the EUR analyses and 45 studies (173,329 samples) in the EUR_SAS analyses 1312 
(Supplementary Tables 2 and 3). Comparison of discovery and RMW study level results were made 1313 
(Supplementary Information).  1314 
For each novel locus, the genomic coordinates and size of the region were defined according to 1315 
recombination rates (Supplementary Table 9) around the lead variant. For known loci, a 1 Mb window was 1316 
used (Supplementary Table 14). Conditional analyses were performed across each region, in both EUR and 1317 
EUR_SAS samples, for the transformed phenotype corresponding to the validated BP trait for novel loci and 1318 
the published BP trait for known loci. 1319 
Gene based tests were performed in both the EUR and EUR_SAS datasets using the Sequence Kernel 1320 
Association Test (SKAT)16 method implemented in RMW as it allows for the SNVs to have different 1321 
directions and magnitudes of effect. Burden tests were also performed but are not presented as only SKAT 1322 
provided significant results. The variants in the gene-based tests using SKAT were weighted using the 1323 
default settings, i.e. a beta distribution density function to up-weight rare variants, Beta(MAFj,1,25) where 1324 
MAFj represents the pooled MAF for variant j across all studies. Analyses were restricted to coding SNVs 1325 
with MAF<5% and <1%. Genes were deemed to be associated if P <2.8x10-6 (Bonferroni adjusted for 1326 
17,996 genes). To confirm the gene associations were not attributable to a solitary SNV, a gene-based test 1327 
conditional on the most associated SNV was performed (Pconditional< 0.001). The QC of all SNVs 1328 
contributing to the gene based tests including the number of samples and studies were checked prior to 1329 
claiming association. We sought replication of associated genes in the CHARGE+ exome chip blood 1330 
pressure consortium.  1331 
 1332 
Pathway analyses with MAGENTA 1333 
We tested seven databases in MAGENTA37 (BioCarta, Kyoto Encyclopedia of Genes and Genomes, 1334 
Ingenuity, Panther, Panther Biological Processes, Panther Molecular Functions and Reactome) for 1335 
overrepresentation of the SNV discovery results from both EUR and EUR_SAS ancestries. Each of the four 1336 
BP phenotypes were tested. Pathways exhibiting P<0.01 and FDR<5% were considered statistically 1337 
significant. 1338 
GeneGo MetaCore Network analyses 1339 
A set of BP genes based on previously published studies and our current results (locus defined as r2>0.4 and 1340 
500kb on either side of the lead SNV; Supplementary Table 19) were tested for enrichment using the 1341 
THOMSON REUTERS MetaCoreTM Single Experiment Analysis workflow tool. The data were mapped 1342 
onto selected MetaCore ontology databases: pathway maps, process networks, GO processes and diseases / 1343 
biomarkers, for which functional information is derived from experimental literature. Outputs were sorted 1344 
based on P- and FDR-values. A gene set was considered enriched for a particular process if P<0.05 and 1345 
FDR<5%. 1346 
 1347 
Genetic Risk Score 1348 
 1349 
To assess the effect of BP on CHD, ischemic stroke (and subtypes: large vessel, small vessel and 1350 
cardioembolic stroke) left ventricular mass, left ventricular wall thickness, heart failure, HDL-c, LDL-c, 1351 
total cholesterol, triglycerides and eGFR, we performed a weighted generalized linear regression of the 1352 
genetic associations with each outcome variable on the genetic associations with BP.  1353 
When genetic variants are uncorrelated, the estimates from such a weighted linear regression analysis using 1354 
summarized data, and a genetic risk score analysis using individual-level data, are equal48. We refer to the 1355 
analysis as a genetic risk score (also known as a polygenic risk score) analysis as this is likely to be more 1356 
familiar to applied readers. As some of the genetic variants in our analysis are correlated, a generalized 1357 
weighted linear regression model is fitted that accounts for the correlations between variants, as follows:  1358 
If βX are the genetic associations (beta-coefficients) with the risk factor (here, BP) and βY are the genetic 1359 
associations with the outcome, then the causal estimate from a weighted generalized linear regression is (βXT 1360 
Ώ-1βX)-1 βXTΏ-1βY, with standard error, 1361 
 ?̂?√(𝛽𝑋
𝑇Ω−1𝛽𝑋)−1, 1362 
where T is a matrix transpose, ?̂? is the estimate of the residual standard error from the regression model, and 1363 
the weighting matrix Ώ has terms 1364 
Ω𝑗1𝑗2 = 𝜎𝑌𝑗1𝜎𝑌𝑗2ρ𝑗1𝑗2 1365 
,where σYj is the standard error of the genetic association with the outcome for the jth SNV, and ρj1j2 is the 1366 
correlation between the j1th and j2 th SNVs. The presence of the estimated residual standard error allows for 1367 
heterogeneity between the causal estimates from the individual SNVs as overdispersion in the regression 1368 
model (in the case of underdispersion, the residual standard error estimate is set to unity). This is equivalent 1369 
to combining the causal estimates from each SNV using a multiplicative random-effects model49. 1370 
 1371 
For each of SBP, DBP and PP, the score was created using both the novel and known BP SNVs or a close 1372 
proxy (r2>0.8). Both the sentinel SNV association and any secondary SNV associations that remained after 1373 
adjusting for the sentinel SNV were included in the genetic risk score. For the 30 validated novel SNV-BP 1374 
associations, βs were taken from the independent replication analyses (Table 1 and 2) to weight the SNV in 1375 
the genetic risk score. For the secondary SNVs from the seven novel loci and five known loci, βs were taken 1376 
from the discovery analyses (Supplementary Tables 10 and 15). For the 82 known SNVs, 43 were either 1377 
genotyped or had proxies on the Exome chip and the βs were taken from discovery results (Supplementary 1378 
Table 13), the remaining βs were taken from published effect estimates. This strategy for selecting betas for 1379 
use in the GRS was taken to minimize the influence of winner’s curse. The associations between the BP 1380 
variants with CHD, HDL-c, LDL-c, total cholesterol, log(triglycerides) and log(eGFR) were obtained using 1381 
the CHD Exome+ Consortium studies, the associations with BMI, waist-hip ratio adjusted BMI and height 1382 
from the GIANT consortium (unpublished data), ischemic stroke from METASTROKE25, and left 1383 
ventricular mass, left ventricular wall thickness and heart failure from EchoGen27 and CHARGE-HF26. A 1384 
causal interpretation of the association of GRS with the outcome as the effect of BP on the outcome assumes 1385 
that the effects of genetic variants on the outcome are mediated via blood pressure and not via alternate 1386 
causal pathways, for example via LV thickness. There are also limitations of the Mendelian randomization 1387 
approach in distinguishing between the causal effects of different measures of blood pressure, due to the 1388 
paucity of genetic variants associated with only one measure of blood pressure. 1389 
 1390 
eQTL analyses 1391 
The MuTHER dataset contains gene expression data from 850 UK twins for 23,596 probes and 2,029,988 1392 
(HapMap 2 imputed) SNVs. All cis–associated SNVs with FDR<1%, within each of the 30 novel regions 1393 
(IMPUTE info score >0.8) were extracted from the MuTHER project dataset for, LCL (n=777), adipose 1394 
(n=776) and skin (n=667) 50. The pilot phase of the GTEx Project (dbGaP Accession phs000424.v3.p1) 1395 
provides expression data from up to 156 individuals for 52,576 genes and 6,820,472 genotyped SNVs 1396 
(imputed to 1000 Genomes project, MAF≥5%)51.  The eQTL analysis was focused on subcutaneous adipose 1397 
tissue (n=94), tibial artery (n=112), heart (left ventricle) (n=83), lung (n=119), skeletal muscle (n=138), 1398 
tibial nerve (n=88), skin (sun exposed, lower leg) (n=96), thyroid (n=105) and whole blood (n=156) which 1399 
have >80 samples and genes expressed at least 0.1 RPKM in 10 or more individuals in a given tissue. All 1400 
transcripts with a transcription start site (TSS) within one of the 30 new BP loci and for which there was a 1401 
cis-associated SNV (IMPUTE info score >0.4) within 1Mb of the TSS at FDR<5%, were identified.  Kidney 1402 
was not evaluated because the sample size was too small (n=8). From each resource, we report eQTL 1403 
signals, which reach the resource-specific thresholds for significance described above, for SNVs that are in 1404 
LD (r2>0.8) with our sentinel SNV. 1405 
For identified eQTLs, we tested whether they colocalised with the BP associated SNV52. Colocalisation 1406 
analyses were considered to be significant if the posterior probability of colocalisation was greater than 0.95. 1407 
Annotation of variants 1408 
In silico prediction of the functional effect of associated variants was based on the annotation from dbSNP, 1409 
the Ensembl Variant Effect Predictor tool and the Exome Variant Server, NHLBI GO Exome Sequencing 1410 
Project (ESP), Seattle, WA. 1411 
Trait variance explained 1412 
The percentage trait variance explained for SBP, DBP, PP was assessed with 5,861 individuals with 1413 
complete information for all phenotypes and covariates from the population-based cohort, 1958BC.   1414 
Two genetic models were investigated: one containing the 43 previously known BP associated SNVs 1415 
covered on the Exome chip; the other additionally including the 30 novel lead SNVs and 9 conditionally 1416 
independent SNVs from both novel and known loci.  These nine conditionally independent SNVs were 1417 
taken from the EUR results, as 1958BC is EUR. They included four from novel loci (PREX1, COL21A1, 1418 
PRKAG1 and MYH6 (there was only 1 in EUR); Supplementary Table 10) and five from known loci (ST7L-1419 
CAPZA1-MOV10, FIGN-GRB14, ENPEP, TBX5-TBX3 and HOXC4; Supplementary Table 15). 1420 
The residual trait was obtained by adjusting each of the BP traits in a regression model with sex and BMI 1421 
variables (not age or age2 as all 1958BC individuals were aged 44 years).  The residual trait was regressed 1422 
on all SNVs within the corresponding model and adjusted for the first ten PCs.  The R2 calculated from this 1423 
regression model was used as the percentage trait variance explained. 1424 
 1425 
Monogenic Enrichment analyses 1426 
To determine if sub-significant signals of association were present in a set of genes associated with 1427 
monogenic forms of disease, we performed an enrichment analysis of the discovery single variant meta-1428 
analyses association results for all four traits, both for EUR and EUR_SAS datasets. 1429 
The monogenic gene set included: WNK1, WNK4, KLHL3, CUL3, PPARG, NR3C2, CYP11B1, CYP11B2, 1430 
CYP17A1, HSD11B2, SCNN1A, SCNN1B, SCNN1G, CLCNKB, KCNJ1, SLC12A1, SLC12A33.  The 1431 
association results of coding SNVs in these genes were extracted and the number of tests with P<0.001 1432 
observed.  In order to determine how often such an observation would be observed by chance, we 1433 
constructed 1,000 matched gene sets. The matching criteria for each monogenic gene was the intersection of 1434 
all genes in the same exon length quintile and all genes in the same coding variant count decile. Within the 1435 
matched sets, the number of variants with P<0.001 was observed.  The empirical P-value was calculated as 1436 
the fraction of matched sets with an equal or larger number of variants less than 0.001. 1437 
 1438 
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